Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MEIPNASDAQ:PHASNASDAQ:UBXNASDAQ:UPXI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMEIPMEI Pharma$2.19+1.9%$2.06$1.46▼$4.10$14.59M0.2143,931 shs3,130 shsPHASPhaseBio Pharmaceuticals$0.00$0.07▼$4.08$3.50M2.57848,888 shs9.65 million shsUBXUnity Biotechnology$0.72+1.0%$0.91$0.66▼$3.10$12.43M1.28129,517 shs42,562 shsUPXIUpexi$11.23+2.6%$7.97$1.90▼$22.57$425.79M-0.27863,242 shs244,304 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMEIPMEI Pharma-3.15%0.00%+5.39%-11.52%-26.12%PHASPhaseBio Pharmaceuticals0.00%0.00%0.00%0.00%+6,910.00%UBXUnity Biotechnology-0.17%-3.09%-36.15%-57.94%-55.03%UPXIUpexi-3.78%+10.27%-22.17%+339.76%+1.54%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMEIPMEI Pharma1.9259 of 5 stars0.03.00.04.12.70.81.3PHASPhaseBio PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AUBXUnity Biotechnology4.3368 of 5 stars3.34.00.04.72.60.81.3UPXIUpexi1.6898 of 5 stars0.05.00.00.02.53.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMEIPMEI Pharma 2.00HoldN/AN/APHASPhaseBio Pharmaceuticals 0.00N/AN/AN/AUBXUnity Biotechnology 2.50Moderate Buy$3.75419.10% UpsideUPXIUpexi 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PHAS, UBX, MEIP, and UPXI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025UBXUnity BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$4.00 ➝ $2.005/16/2025UBXUnity BiotechnologyMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Neutral$6.00 ➝ $1.004/23/2025UBXUnity BiotechnologyChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.004/23/2025UBXUnity BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.003/25/2025UBXUnity BiotechnologyChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $4.003/24/2025UBXUnity BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $4.003/10/2025UBXUnity BiotechnologyChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.003/10/2025UBXUnity BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00(Data available from 6/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMEIPMEI Pharma$65.30M0.22$4.98 per share0.44$3.32 per share0.66PHASPhaseBio Pharmaceuticals$818K0.00N/AN/A($1.93) per share0.00UBXUnity Biotechnology$240K51.81N/AN/A$1.69 per share0.43UPXIUpexi$16.56M25.71N/AN/A$2.85 per share3.94Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMEIPMEI Pharma$17.78M-$4.75N/AN/AN/AN/A-84.92%-67.53%N/APHASPhaseBio Pharmaceuticals-$131.07M-$2.13N/AN/AN/A-12,572.13%N/A-174.38%N/AUBXUnity Biotechnology-$39.86M-$1.62N/AN/AN/AN/A-119.70%-45.86%7/22/2025 (Estimated)UPXIUpexi-$23.66MN/A0.00∞N/AN/AN/AN/A7/8/2025 (Estimated)Latest PHAS, UBX, MEIP, and UPXI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/16/2025Q1 2025UPXIUpexiN/A-$2.87N/A-$2.87N/A$3.16 million5/13/2025Q3 2025MEIPMEI PharmaN/A-$0.39N/A-$0.39N/AN/A4/22/2025Q1 2025UBXUnity Biotechnology-$0.43-$0.43N/A-$0.43N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMEIPMEI PharmaN/AN/AN/AN/AN/APHASPhaseBio PharmaceuticalsN/AN/AN/AN/AN/AUBXUnity BiotechnologyN/AN/AN/AN/AN/AUPXIUpexiN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMEIPMEI PharmaN/A10.6610.66PHASPhaseBio PharmaceuticalsN/A0.470.47UBXUnity BiotechnologyN/A3.453.45UPXIUpexi0.350.580.53Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMEIPMEI Pharma52.38%PHASPhaseBio Pharmaceuticals49.02%UBXUnity Biotechnology29.49%UPXIUpexi5.68%Insider OwnershipCompanyInsider OwnershipMEIPMEI Pharma3.12%PHASPhaseBio Pharmaceuticals9.90%UBXUnity Biotechnology5.80%UPXIUpexi31.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMEIPMEI Pharma1006.66 million6.46 millionOptionablePHASPhaseBio Pharmaceuticals6049.86 million44.92 millionNot OptionableUBXUnity Biotechnology6017.21 million15.87 millionOptionableUPXIUpexi13037.92 million863,000OptionablePHAS, UBX, MEIP, and UPXI HeadlinesRecent News About These CompaniesWall Street Zen Upgrades Upexi (NASDAQ:UPXI) to HoldJune 2 at 12:31 AM | marketbeat.comUpexi (NASDAQ:UPXI) Raised to Hold at Wall Street ZenJune 1 at 1:33 AM | americanbankingnews.comUpexi, Inc. (NASDAQ:UPXI) Short Interest UpdateMay 31, 2025 | marketbeat.comUpexi, Inc. (NASDAQ:UPXI) Sees Significant Drop in Short InterestMay 31, 2025 | americanbankingnews.comUpexi to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference on June 24-25May 30, 2025 | globenewswire.comUpexi releases presentation detailing Solana treasury strategyMay 29, 2025 | finance.yahoo.comUpexi Partners with Crypto-Native Marketing and Design Firm, GMI Digital, to Drive Solana-Focused StrategyMay 29, 2025 | globenewswire.comUpexi, Inc. Acquires 77,879 Locked SOL for $11.8 Million, Increasing Holdings to 679,677 SOLMay 28, 2025 | quiverquant.comUpexi, Inc. Buys Additional Locked SOL at a Discount for $11.8 millionMay 28, 2025 | taiwannews.com.twUpexi, Inc. Buys Additional Locked SOL at a Discount for $11.8 millionMay 28, 2025 | globenewswire.comUpexi Releases Investor Presentation Detailing Solana Treasury StrategyMay 27, 2025 | accessnewswire.comUpexi Inc.May 26, 2025 | wsj.comUpexi Appoints Brian Rudick, CFA as Chief Strategy OfficerMay 22, 2025 | accessnewswire.comUpexi Reports First Quarter 2025 Financial Results and Provides Update on Solana Treasury StrategyMay 16, 2025 | accessnewswire.comUpexi Buys Discounted Locked SOL, Surpasses $100 Million of SOL and Becomes the Largest Publicly-Traded Solana Treasury CompanyMay 12, 2025 | finanznachrichten.deUpexi Increases Solana Treasury to 201,500 Solana Tokens for $30 Million and Begins to Generate Staking RevenueMay 6, 2025 | finanznachrichten.deClassover Bets On Solana To Reshape Its Balance Sheet, Financial Strategy – Stock Continues Rally With 70% Pre-Market JumpMay 2, 2025 | msn.comThis is Why Companies are Diversifying with Cryptocurrencies, Like BitcoinApril 30, 2025 | baystreet.caCORRECTION FROM SOURCE: Upexi Purchases 45,733 Solana Tokens as it Begins Deploying $100 Million Treasury in Solana StrategyApril 29, 2025 | finanznachrichten.deUpexi Purchases 45,733 Solana Tokens as it Begins Deploying $100 Million Treasury in Solana StrategyApril 29, 2025 | finance.yahoo.comInsider Buying: Upexi, Inc. (NASDAQ:UPXI) CFO Purchases 43,860 Shares of StockApril 26, 2025 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingUber Stock Ready to Ride Higher on Waymo PartnershipBy Gabriel Osorio-Mazilli | May 28, 2025View Uber Stock Ready to Ride Higher on Waymo Partnership3 Companies to Buy on This Early Cycle RecoveryBy Gabriel Osorio-Mazilli | June 3, 2025View 3 Companies to Buy on This Early Cycle RecoveryPHAS, UBX, MEIP, and UPXI Company DescriptionsMEI Pharma NASDAQ:MEIP$2.19 +0.04 (+1.86%) As of 03:59 PM EasternMEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex which has completed Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer. MEI Pharma, Inc. has a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.PhaseBio Pharmaceuticals NASDAQ:PHASPhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor, pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension, and PB6440, an oral agent for the treatment of resistant hypertension. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA.Unity Biotechnology NASDAQ:UBX$0.72 +0.01 (+1.02%) As of 04:00 PM EasternUnity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.Upexi NASDAQ:UPXI$11.23 +0.28 (+2.56%) As of 04:00 PM EasternUpexi, Inc. manufactures and sells various branded products in the health, wellness, pet, beauty, and other markets. The company was formerly known as Grove, Inc. and changed its name to Upexi, Inc. in August 2022. The company was incorporated in 2018 and is headquartered in Clearwater, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Robinhood Stock Keeps Giving Investors Reasons To Buy CrowdStrike Stock Dips on Guidance Miss: It May Rebound Fast Guidewire Rockets Higher: A Move Above $300 Is Probable TSMC Joins NVIDIA in UAE Push, Fueling Growth Outlook Constellation Energy and Meta Strike Nuclear Deal, Shares Whipsaw Archer's Midnight Air Taxi Soars, But Stock Doesn’t Budge Analog Devices' Cyclical Recovery Story Has Just Begun Microsoft Stock Near Peak, Pullback Seen as Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
